LEFT VENTRICULAR HYPERTROPHY RISK FACTOR IN PATIENTS WITH END STAGE RENALE DISEASE TREATED WITH HAEMODIALYSIS

Zylbeari, Lutfi and Haxhirexha, Kastriot and Bexheti, Sadi and Ademi, Veton and Bexheti, Zamira (2019) LEFT VENTRICULAR HYPERTROPHY RISK FACTOR IN PATIENTS WITH END STAGE RENALE DISEASE TREATED WITH HAEMODIALYSIS. ACTA MEDICA BALKANICA International Journal of Medical Sciences, 4 (7-8). pp. 71-78. ISSN 2545-4870

Text 9.pdf Download (10MB)

Abstract

Cardiovascular diseases (CVD) are the main cause of morbidity and mortality in patients suffering from End-Stage Renal Disease (ESRD) and undergoing treatment by long-term haemodialysis. One of the complications for uremic patients during the treatment by haemodialysis (HD) is Left Ventricular Hypertrophy (LVH) which begins during the early phases of the diseases which is not related to the underlying renal disease. Involvement of CVD (acute myocardial infarction, arrhythmia, congestive cardiac failure, angina pectoris stable and unstable) lately are described as cardio-renal diseases (Goldmani et al., 2016). The cardiovascular complications may appear at any phase of ESRD regardless the Glomerular Filtration Rate (GFR). CVD are present in 75 % of the patients treated with long-term HD beginning in Phase III NKF-K/DOQI (National Kidney Foundation – Kidney/ Disease Outcomes Quality Initiative).The LVH assessment is heterogeneous, but with the standard examination assistance(echocardiography, electrocardiography, computer tomography, magnetic resonance imaging) it can be used to diagnose exactly the mentioned disease. Purpose of study: The aim of the study was to detect and verify the prevalence of left ventricular hypertrophy in patients with ESRD treated with long term hemodialysis (HD). Conclusion: The risk of left ventricular hypertrophy and cardiovascular diseases in patients with renal chronic disease and patients treated with long-term haemodialysis increases with progression of disease and decrease of GFR. LVH and CVD are independent risk factors for high mortality rates in uremic patients treated with long-term haemodialysis. Early detection and adequate treatment LVH should begin in the early phases of the diseases and should be the first step undertaken by nephrologists, with the sole purpose of their prevention.

Item Type:	Article
Subjects:	R Medicine > R Medicine (General)
Divisions:	Faculty of Medicine, Health and Life Sciences > School of Medicine
Depositing User:	Unnamed user with email zshi@unite.edu.mk
Date Deposited:	17 Sep 2019 07:16
Last Modified:	17 Sep 2019 07:16
URI:	http://eprints.unite.edu.mk/id/eprint/283

Actions (login required)

View Item